RT Journal Article
SR Electronic
T1 A novel mutation in EROS (<em>CYBC1</em>) causes Chronic Granulomatous Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.21.23286144
DO 10.1101/2023.04.21.23286144
A1 Mortimer, Paige M
A1 Nichols, Esme
A1 Thomas, Joe
A1 Shanbhag, Rachna
A1 Singh, Neha
A1 Coomber, Eve L
A1 Malik, Talat H
A1 Pickering, Matthew C
A1 Randzavola, Lyra
A1 Rae, William
A1 Bhattad, Sagar
A1 Thomas, David C
YR 2023
UL http://medrxiv.org/content/early/2023/04/25/2023.04.21.23286144.abstract
AB Chronic Granulomatous Disease (CGD) is an inborn error of immunity characterised by opportunistic infection and sterile granulomatous inflammation. CGD is caused by a failure of reactive oxygen species (ROS) production by the phagocyte NADPH oxidase. Mutations in the genes encoding phagocyte NADPH oxidase subunits cause CGD. We and others have described a novel form of CGD (CGD5) secondary to lack of EROS (CYBC1), a highly selective chaperone for gp91phox. EROS-deficient cells express minimal levels of gp91phox and its binding partner p22phox, but EROS also controls the expression of other proteins such as P2×7. The full nature of CGD5 is currently unknown. We describe a homozygous frameshift mutation in CYBC1 leading to CGD. Individuals who are heterozygous for this mutation are found in South Asian populations (allele frequency = 0.00006545), thus it is not a private mutation. Therefore, it is likely to be the underlying cause of other cases of CGD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from a Wellcome-Beit Prize Trust Clinical Research Career Development Fellowship (20661206617/A/17/Z and 206617/A/17/A) and the Sidharth Burman endowment. MCP is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z) and THM is supported by this fellowship. We acknowledge support from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare National Health Service Trust and Imperial College London, and from the NIHR Clinical Research Network. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIH, or the Department of Health. We thank the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility for their support. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent for this study was obtained from the patient and her family and ethical approval was granted by the Institutional Ethics Committee of Aster CMI Hospital, Bengaluru. IEC Regd. No. ECR/1084/Inst/KA/2018.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptATTAnti-Tuberculosis TreatmentCGDChronic Granulomatous DiseaseDHRDihydrorhodamineEROSEssential for Reactive Oxygen SpeciesIEIInherited Error of ImmunityNADPHNicotinamide adenine dinucleotide phosphateROSReactive Oxygen Species